Close Menu

siRNA

NEW YORK (GenomeWeb News) – Using genome-wide RNAi screens, Richard Youle at the US National Institute of Neurological Disorders and Stroke and his colleagues have identified a bevy of regulators of

Looking to harness the gene-silencing efficiency of siRNAs to enhance the potency of disease-targeting microRNAs, a team of researchers from Washington University has developed new molecules that incorporate features of both classes of small RNAs.

Theradiag has named four members of its newly formed scientific advisory board who will help the company develop a microRNA-based diagnostic for characterizing HIV tropism.

Merck this week announced a broad restructuring that will include the elimination of roughly 8,500 jobs and a reduction in the company's annual operating expenses by $2.5 billion by the end of 2015.

Life Technologies announced this week that it has signed a licensing agreement giving Suzhou Ribo Life Sciences the exclusive rights to use its Invivofectamine Rx delivery technology in the development and manufacturing of siRNA therapeutics in China.

With Marina Biotech's back against the wall, the RNAi drugs field may soon see the departure of its third player this year, following the bankruptcy of Traversa Therapeutics and the acquisition of Tacere Therapeutics by Benitec Biopharma.

Falcon Genomics continues to work toward its goal of seeing its research-use-only Cancer Biochip System adopted in a clinical setting.

By Doug Macron
The National Institutes of Health last month handed out nearly $1.3 million in grant funding to support four research projects focused on developing siRNA-delivery technologies.

Takara Bio Europe has introduced the Xfect siRNA transfection reagent.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.